Emergent Biosolutions (NYSE:EBS) Earns Buy Rating from HC Wainwright

Emergent Biosolutions (NYSE:EBS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 21.43% from the company’s current price.

Several other analysts also recently issued reports on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Emergent Biosolutions in a research report on Monday, December 8th. Wall Street Zen upgraded shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 30th. Finally, Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $15.00.

Emergent Biosolutions Stock Performance

Shares of Emergent Biosolutions stock opened at $12.35 on Tuesday. The business has a 50-day simple moving average of $10.48 and a 200 day simple moving average of $8.56. Emergent Biosolutions has a one year low of $4.02 and a one year high of $13.41. The company has a debt-to-equity ratio of 1.14, a current ratio of 5.76 and a quick ratio of 3.15. The firm has a market capitalization of $648.78 million, a price-to-earnings ratio of 9.50 and a beta of 2.32.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. The firm had revenue of $222.50 million during the quarter. Emergent Biosolutions had a return on equity of 20.85% and a net margin of 9.62%. On average, research analysts anticipate that Emergent Biosolutions will post -0.63 earnings per share for the current fiscal year.

Insider Activity at Emergent Biosolutions

In related news, Director Ronald Richard sold 21,984 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $11.97, for a total transaction of $263,148.48. Following the completion of the sale, the director directly owned 98,417 shares of the company’s stock, valued at approximately $1,178,051.49. This trade represents a 18.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Coleen Glessner sold 30,608 shares of the business’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total value of $306,080.00. Following the completion of the transaction, the executive vice president directly owned 144,319 shares in the company, valued at approximately $1,443,190. This represents a 17.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Emergent Biosolutions

Several institutional investors have recently added to or reduced their stakes in EBS. Sherbrooke Park Advisers LLC purchased a new stake in Emergent Biosolutions during the third quarter worth about $192,000. Morse Asset Management Inc grew its position in shares of Emergent Biosolutions by 4.7% during the 3rd quarter. Morse Asset Management Inc now owns 217,925 shares of the biopharmaceutical company’s stock valued at $1,922,000 after acquiring an additional 9,881 shares during the period. Jain Global LLC purchased a new stake in shares of Emergent Biosolutions during the 3rd quarter worth approximately $4,487,000. Creative Planning increased its stake in shares of Emergent Biosolutions by 44.7% during the 3rd quarter. Creative Planning now owns 21,742 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 6,718 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of Emergent Biosolutions by 607.0% in the 3rd quarter. Squarepoint Ops LLC now owns 172,797 shares of the biopharmaceutical company’s stock worth $1,524,000 after purchasing an additional 148,357 shares during the period. Institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.